George R Simon, MD, FACP, FCCP on selecting ALK inhibitors in ALK-positive non–small cell lung cancer.
George R. Simon, MD
Advertisement
Articles by George R. Simon, MD
George Simon, MD, FACP, FCCP, discusses the evaluation of datopotamab deruxtecan in TROP-2–overexpressing solid tumors.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
2
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
3
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
4
Dr Hurvitz on Updated PFS Data From the SERENA-6 Trial in Breast Cancer
5